[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-373711-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-373711-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","sox-9-as-a-prognostic-marker-in-gastric-adenocarcinoma","SOX-9 as a Prognostic Marker in Gastric Adenocarcinoma","","SRY-box transcription factor 9 (SOX9) has been implicated in multiple gastrointestinal malignancies, yet findings in gastric cancer remain inconsistent. This study evaluates whether SOX9 immunohistochemistry staining relates to pathological and clinical features of gastric adenocarcinoma and its prognostic value. Gastric tissue from 150 patients was retrospectively analyzed after scoring nuclear staining intensity and proportion. High SOX9 expression correlated with larger tumors, increased perineural/vascular invasion, advanced T and lymph node stages, and higher rates of lymphatic or distant metastases, indicating worse disease progression and potential prognostic utility.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/sox-9-as-a-prognostic-marker-in-gastric-adenocarcinoma/373711/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/sox-9-as-a-prognostic-marker-in-gastric-adenocarcinoma/373711.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the aim of this study on SOX9 in gastric adenocarcinoma?","Question",{"text":63,"@type":64},"To assess the relationship between SOX9 immunohistochemistry results and pathological/clinical characteristics of gastric adenocarcinoma and evaluate SOX9 as a prognostic marker.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were SOX9 immunostaining results scored?",{"text":68,"@type":64},"Staining was scored based on the proportion and intensity of stained nuclei across the tumor, then a final score was calculated as intensity score multiplied by proportion score.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical features were associated with high SOX9 expression?",{"text":72,"@type":64},"Patients with higher SOX9 expression or stronger intensity showed significantly larger tumor sizes, higher perineural and vascular invasion rates, more advanced T or lymph node staging, and greater likelihood of lymphatic or distant metastases.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},373711,1790240504,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},4398046744996,"RESEARCH ARTICLE  \nSOX-9 as a prognostic marker in gastric adenocarcinoma  \nEfe Yetigin , Aysun Gökçe , and Kutsal Do˘gan ∗  \nSRY-box transcription factor 9 (SOX9) has been reported to be overexpressed in a wide variety of gastrointestinal malignancies. While its role has been studied in gastric cancer (GC), the results remain conflicting. This study aimed to evaluate the relationship between SOX9 immunohistochemistry results and the pathological and clinical characteristics of gastric adenocarcinoma, assessing its potential as a prognostic marker. Gastric tissue samples from 150 patients with gastric cancer were included in the study. Tissue sections were stained using an anti-SOX9 antibody, and relevant data were retrospectively collected from digital records. Immunostaining results were scored based on the proportion and intensity of stained nuclei throughout the tumor. A final immunostaining score was calculated by multiplying the SOX9 intensity score by the proportion score. Strong SOX9 nuclear staining was observed in 68 patients (45.3%), while moderate staining was seen in 60 patients (40%). SOX9 nuclear staining was absent in three patients (2%). A final SOX9 immunostaining score of ≥10, classified as high expression, was identified in 60 patients (40%) . Patients with higher SOX9 expression or strong intensity scores exhibited significantly larger tumor sizes, higher rates of perineural and vascular invasion, more advanced Tumor (T) or lymph node staging, and greater likelihoods of lymphatic or distant metastases compared to those with lower SOX9 expression or intensity scores (all P \u003C 0.05). These findings suggest that SOX9 staining intensity and expression are associated with  \nincreased tumor malignancy and disease progression. Therefore, SOX9 may serve as a prognostic pathological indicator in GC patients. Keywords: Gastric cancer, GC, SRY-box transcription factor 9, SOX9, adenocarcinoma, prognosis, stomach.  \nIntroduction  \nGastric cancer (GC) is diagnosed in over one million individuals annually [1] . Despite advancements in management, the prognosis remains poor [1, 2] . The primary challenge is that GC is often diagnosed at an inoperable stage due to its non-specific early symptoms and the presence of regional or distant metastases at diagnosis [3] . This subtle progression to advanced stages complicates staging with the widely-used tumor-node-metastasis (TNM) system, as patients at the same TNM stage often exhibit varying outcomes [4]. In the absence of significant diagnostic or prognostic breakthroughs, improving the sensitivity of TNM staging remains a critical goal. This can be achieved through the identification of new prognostic indicators [5] .  \nAdvancements in molecular biology have identified several biomarkers that enhance prognostic accuracy and therapeutic strategies for GC. For example, anti-ERBB2 therapy is effective in patients with unresectable or metastatic/recurrent ERBB2-positive GC, with ERBB2 testing serving as a predictor of therapeutic response [6] . ERBB2 status is primarily determined via immunohistochemistry, while in situ hybridization is recommended for equivocal cases. EGFRamplification has been identified as an independent prognostic factor in stage II/III GC [7] . Similarly, c-MET status has been proposed as an independent prognostic indicator for patients with unresectable or recurrent GC undergoing standard chemotherapy [8] .  Moreover, GC cases associated with  \nEpstein–Barr virus (EBV) positivity or microsatellite instability (MSI)/mismatch repair (MMR) deficiency tend to have better prognoses compared to EBV-negative or microsatellite-stable (MSS)/MMR-proficient cases [9, 10] . PD-1/PD-L1 expression has been found to be significantly elevated in GC subtypes characterized by MSI and EBV positivity, making these subtypes promising candidates for immunotherapy targeting the PD-1/ PD-L1 pathway [9] .  \nSex-determining region Y-related high mobility group box 9 (SOX9) is a key regulator i","cbCaibrcTpBTlK7H","https://ap.wps.com/l/cbCaibrcTpBTlK7H","pdf",6012378,"English","# Introduction\n## Biomarkers and prognostic challenges in gastric cancer\n## Biological roles of SOX9 in development and cancer","[{\"question\":\"What was the aim of this study on SOX9 in gastric adenocarcinoma?\",\"answer\":\"To assess the relationship between SOX9 immunohistochemistry results and pathological/clinical characteristics of gastric adenocarcinoma and evaluate SOX9 as a prognostic marker.\"},{\"question\":\"How were SOX9 immunostaining results scored?\",\"answer\":\"Staining was scored based on the proportion and intensity of stained nuclei across the tumor, then a final score was calculated as intensity score multiplied by proportion score.\"},{\"question\":\"What clinical features were associated with high SOX9 expression?\",\"answer\":\"Patients with higher SOX9 expression or stronger intensity showed significantly larger tumor sizes, higher perineural and vascular invasion rates, more advanced T or lymph node staging, and greater likelihood of lymphatic or distant metastases.\"}]","SOX-9 as a Prognostic Marker in Gastric Adenocarcinoma | PDF",1790200279,25]